PL415644A1 - Concentration of iron in blood as a risk factor for cancers in women after the age of 50 - Google Patents

Concentration of iron in blood as a risk factor for cancers in women after the age of 50

Info

Publication number
PL415644A1
PL415644A1 PL415644A PL41564415A PL415644A1 PL 415644 A1 PL415644 A1 PL 415644A1 PL 415644 A PL415644 A PL 415644A PL 41564415 A PL41564415 A PL 41564415A PL 415644 A1 PL415644 A1 PL 415644A1
Authority
PL
Poland
Prior art keywords
concentration
iron
risk
serum
age
Prior art date
Application number
PL415644A
Other languages
Polish (pl)
Inventor
Jan Lubiński
Anna Jakubowska
Wojciech Marciniak
Magdalena Muszyńska
Katarzyna Kaczmarek
Tomasz Huzarski
Jacek Gronwald
Cezary Cybulski
Original Assignee
Read-Gene Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Read-Gene Spółka Akcyjna filed Critical Read-Gene Spółka Akcyjna
Priority to PL415644A priority Critical patent/PL415644A1/en
Publication of PL415644A1 publication Critical patent/PL415644A1/en

Links

Landscapes

  • Investigating Or Analysing Biological Materials (AREA)

Abstract

W zgłoszeniu ustalono, że występuje korelacja między stężeniem żelaza w surowicy a ryzykiem raków u kobiet po 50 roku życia. Przedmiotem zgłoszenia jest sposób określania ryzyka raka, charakteryzuje się tym, że obejmuje ocenę stężenia żelaza w próbce biologicznej badanej kobiety, przy czym stężenie żelaza wskazuje znacząco zwiększone/obniżone ryzyko rozwoju raków u kobiet po 50 roku życia: - przy stężeniu żelaza w surowicy < 785 µg/l (lub stężeniu w dowolnym materiale biologicznym odpowiadającym stężeniu w surowicy) ryzyko jest zwiększone; - przy stężeniu żelaza w surowicy 975-11025 µg/l (lub stężeniu w dowolnym materiale biologicznym odpowiadającym stężeniu w surowicy) ryzyko jest obniżone.The report found that there is a correlation between serum iron levels and cancer risk in women over 50 years of age. The subject of the application is a method for determining the risk of cancer, characterized by the fact that it includes the assessment of iron concentration in the biological sample of the examined woman, while the concentration of iron indicates a significantly increased / reduced risk of developing cancers in women over 50: - with serum iron <785 µg / l (or concentration in any biological material corresponding to serum concentration) the risk is increased; - at a serum iron concentration of 975-11025 µg / l (or concentration in any biological material corresponding to the serum concentration) the risk is reduced.

PL415644A 2015-12-30 2015-12-30 Concentration of iron in blood as a risk factor for cancers in women after the age of 50 PL415644A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL415644A PL415644A1 (en) 2015-12-30 2015-12-30 Concentration of iron in blood as a risk factor for cancers in women after the age of 50

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL415644A PL415644A1 (en) 2015-12-30 2015-12-30 Concentration of iron in blood as a risk factor for cancers in women after the age of 50

Publications (1)

Publication Number Publication Date
PL415644A1 true PL415644A1 (en) 2017-07-03

Family

ID=59201416

Family Applications (1)

Application Number Title Priority Date Filing Date
PL415644A PL415644A1 (en) 2015-12-30 2015-12-30 Concentration of iron in blood as a risk factor for cancers in women after the age of 50

Country Status (1)

Country Link
PL (1) PL415644A1 (en)

Similar Documents

Publication Publication Date Title
MX2022010224A (en) Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease.
MX389083B (en) Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging.
MX2021006791A (en) Methods and compositions for detecting misfolded proteins.
MX362041B (en) METHOD FOR THE PROGNOSIS AND TREATMENT OF METASTASIC CANCER OF ORIGINATED BREAST CANCER BONES.
WO2017062496A3 (en) Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer
BR112015022934A2 (en) neuroactive steroids, compositions, and use thereof
MY195045A (en) Specific Biomarker Set For Non-Invasive Diagnosis of Liver Cancer
MY187050A (en) Cancer cell-specific antibody, anticancer agent, and cancer testing method
MX392040B (en) PROSTATE ANTIGEN STANDARDS AND THEIR USES.
MX377026B (en) BIOMARKERS FOR DISEASE PROGRESSION IN MELANOMA.
BR112016017926A2 (en) Assay for human periostin
MX384485B (en) EARLY DETECTION OF PREECLAMPSIA.
MX2022002886A (en) RADIOLABELED MET UNION PROTEINS FOR IMAGING BY IMMUNO-PET.
MX384636B (en) METHOD FOR DETECTING NEUTRALIZING ANTIBODIES AGAINST RECOMBINANT HUMAN INSULIN IN HUMAN SERUM.
PL414266A1 (en) Concentration of selenium in blood as a risk factor for cancers in women
EA202190671A1 (en) IMMUNOGENETIC SCREENING TEST FOR CANCER
PL414265A1 (en) Concentration of copper in blood as a risk factor for extramammary breast cancers in women
PL415636A1 (en) Concentration of iron in blood as a risk factor for cancers in men
PL406989A1 (en) Profile of micro RNA in blood as the test for detecting lung cancer
PL415634A1 (en) Concentration of selenium in blood as a risk factor for cancers in men
PL414267A1 (en) Concentration of iron in blood as a risk factor for cancers in women who are carriers of a mutation in BRCA1 gene
PL415632A1 (en) Concentration in blood and changes within IL6 gene as risk factors for cancers in women
PL420483A1 (en) Selenium to arsenic ratio as the marker of malignant tumour risk among Polish women
PL439314A1 (en) Method for determining the risk of cancers in women, depending on concentration of cadmium in the blood
PL439313A1 (en) Method for determining the risk of cancers in women, depending on concentration of arsenic in the blood